RagD gene expression and NRF2 mutations in lung squamous cell carcinomas

Oncology Letters

Volumn 4, Issue 6, 2012, Pages 1167-1170

  Sasaki, Hidefumi ^a   Shitara, Masayuki ^a   Yokota, Keisuke ^a   Hikosaka, Yu ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Lung cancer; Mutation; NRF2; RagD; Squamous cell carcinoma

Indexed keywords

BETA ACTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; RAGD PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84867256331     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.938     Document Type: Article

References (23)

1. Ginsberg RJ, Kris MK and Armstrong JG: Cancer of the lung. In: Principles and Practice of Oncology. DeVita VT Jr, Hellman S and Rosenberg SA (eds). 4th edition. Lippincott, Philadelphia, pp.673-682, 1993.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. Ca Cancer J Clin 59: 225-249, 2009.
3. Zhou X, Tan M, Stone Hawthorne V, et al: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788, 2004.
4. Bjornsti MA and Houghton PJ: The TOR pathway: target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004.
5. Borders EB, Bivona C and Medina PJ: Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm 67: 2095-2106, 2010.
6. Liu D, Huang Y, Chen B, et al: Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer 117: 3763-3773, 2011.
7. Gately K, Al-Alao B, Dhillon T, et al: Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer 75: 217-222, 2012.
8. Sancak Y, Peterson TR, Shaul YD, et al: The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-1501, 2008.
9. Shibata T, Saito S, Kokubu A, et al: Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. Cancer Res 70: 9095-9105, 2010.
10. Solis LM, Behrens C, Dong W, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16: 3743-3753, 2010.
11. Sasaki H, Hikosaka Y, Okuda K, et al: NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J Thorac Oncol 5: 786-789, 2010.
12. Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in Nrf2 impair its recognition by Keap1-Clu3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.
13. Hu Y, Ju Y, Lin D, et al: Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep: Oct 1, 2011 (Epub ahead of print).
14. Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318, 2009.
15. Kim E, Goraksha-Hicks P, Li L, et al. regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10: 935-945, 2008.
16. Itoh K, Chiba T, Takahashi S, et al: An Nef2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997.
17. Rushmore TH and Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II detoxifying enzymes. Curr Drug Metab 3: 481-490, 2002.
18. Ngyyen T, Yang CS and Pickett CB: The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 37: 433-441, 2004.
19. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
20. Arisawa T, Tahara T, Shibata T, et al: Nrf2 gene promoter polymorphism and gastric carcinogenesis. Hepatogastroenterology. 55: 750-754, 2008.
21. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3: 721-732, 2003.
22. Zhou J, Scmid T, Schnitzer S, et al: Tumor hypoxia and cancer progression. Cancer Lett 237: 10-21, 2006.
23. Wang L, Yue W, Zhang L, et al: mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry. Surg Today: Nov 30, 2011 (Epub ahead of print).